Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysis

Medicine and Dentistry

• Health Care Cost 100%
• Malignant Neoplasm 85%
• Bladder Cancer 85%
• Screening 85%
• Tumor Marker 42%
• Bladder Tumor 42%
• NMP22 42%
• Analysis 42%
• Marker 28%
• Man 28%
• Incidence 28%
• Patient 28%
• Accuracy 28%
• Prostate Cancer 14%
• Bladder 14%
• Breast Cancer 14%
• High Risk Population 14%
• Colon Cancer 14%
• Low Risk Population 14%
• Age 14%

Nursing and Health Professions

• Screening 85%
• Malignant Neoplasm 85%
• Bladder Cancer 85%
• Tumor Marker 42%
• Analysis 42%
• Bladder Tumor 42%
• Marker 28%
• Incidence 28%
• Bladder Cancer Detection Kit 28%
• Colon Cancer 14%
• Food and Drug Administration 14%
• Prostate Cancer 14%
• High Risk Population 14%
• Breast Cancer 14%
• Decision Tree 14%
• Laboratory 14%
• Procedures 14%
• Literature Review 14%
• Low Risk Population 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Bladder Cancer 85%
• Malignant Neoplasm 85%
• Bladder Tumor 42%
• Tumor Marker 42%
• Incidence 28%
• Colon Cancer 14%
• Breast Cancer 14%
• Prostate Cancer 14%